Email updates

Keep up to date with the latest news and content from Lipids in Health and Disease and BioMed Central.

Open Access Highly Accessed Review

Emerging therapeutic strategies to enhance HDL function

Santiago Redondo12*, José Martínez-González3, Concha Urraca1 and Teresa Tejerina1

Author Affiliations

1 Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid, Spain

2 Service of Hematology, Hospital Nuestra Señora de Sonsoles, Ávila, Spain

3 Cardiovascular Research Center (CSIC-ICCC), IIB-Sant Pau, Barcelona, Spain

For all author emails, please log on.

Lipids in Health and Disease 2011, 10:175  doi:10.1186/1476-511X-10-175

Published: 10 October 2011

Abstract

Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and cardiovascular disease (CVD). The most relevant cardioprotective mechanism mediated by HDL is thought to be reverse cholesterol transport (RCT). New insights in HDL biology and RCT have allowed the development of promising agents aimed to increase HDL function and promote atherosclerosis regression. In this regard, apo-AI analogs and CETP inhibitors dalcetrapib and anacetrapib have aroused a great interest and opened new expectations in the treatment of CVD.